ストックスクリーナーアプリを入手
1.79
2.29%
0.04
アフターアワーズ：
1.81
0.02
+1.12%
前日終値:
$1.75
開ける：
$1.78
24時間の取引高:
599.67K
Relative Volume:
0.93
時価総額：
$76.35M
収益：
$55,200
当期純損益:
$-21.24M
株価収益率:
-3.0416
EPS:
-0.5885
ネットキャッシュフロー:
$-19.37M
1週間 パフォーマンス:
+8.48%
1か月 パフォーマンス:
+2.29%
6か月 パフォーマンス:
-53.63%
1年 パフォーマンス:
+2.87%
1日の値動き範囲:
$1.77
$1.86
1週間の範囲:
$1.60
$1.86
52週間の値動き範囲:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Compare GANX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.79 | 74.64M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-08-14 | 再開されました | Oppenheimer | Outperform |
| 2021-04-12 | 開始されました | BTIG Research | Buy |
| 2021-04-12 | 開始されました | Oppenheimer | Outperform |
Gain Therapeutics Inc (GANX) 最新ニュース
GANX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewswire Inc.
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail - Citeline News & Insights
Niemann-Pick Type Pipeline Gains Momentum: 10+ Companies Lead - openPR.com
Which stocks are moving after the closing bell on Monday? - ChartMill
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
TVTX: FILSPARI cements its role in rare kidney disease, with robust growth and pipeline innovation - TradingView
Tango Therapeutics Shares Surge 32% on Strong Clinical Momentum in Precision Oncology - International Business Times Australia
Monday's pre-market session: top gainers and losers - ChartMill
GAIN THERAPEUTICS INC (GANX) Stock Chart - ChartMill
OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake - Insider Monkey
Gain Therapeutics (GANX) price target increased by 11.76% to 7.75 - MSN
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic... - markets.businessinsider.com
Wondering what's happening in today's pre-market session? - ChartMill
GANX Q1 2026 Earnings: Positive EPS Surprise Amidst Pre-Revenue StageHealthcare Earnings Report - newsline.com
Protagonist Therapeutics Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy - Yahoo Finance
Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday - Benzinga
TG Therapeutics Surges 10.2% Amid Sector-Wide Rally - AlphaStreet
Gain Therapeutics Inc. (GANX) Declines 1.64% as Stock Hovers Near Key Support LevelQuote Data - newsline.com
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Prostate cancer study in The Lancet Oncology finds 30% DFS boost - Stock Titan
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Travere Therapeutics (TVTX) - The Globe and Mail
GANX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Double-Digit Share RallyNegative Surprise Momentum - The Legal Advocate
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics (GANX) Surges 14.7% as Volume Picks Up, Testing Resistance at $2.13Buy Signal Reports - The Legal Advocate
Trevi Therapeutics (TRVI) Holds Near Resistance After Modest GainBuffered ETF - The Legal Advocate
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics stock maintained at Outperform by Oppenheimer - Investing.com
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate - Yahoo Finance
Gain Therapeutics (GANX) Climbs Higher as Bullish Momentum Builds Near ResistanceBollinger Walk - The Legal Advocate
Gain Therapeutics Releases First Quarter 2026 Financial Results and Corporate Update - geneonline.com
Gain Therapeutics Announces Interim Clinical and Biomarker Data from Phase 1B Study of GT-02287 in Parkinson's Disease - marketscreener.com
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate - TipRanks
GT-02287 shows biomarker, symptom stability in Gain (GANX) Parkinson’s study - Stock Titan
Gain Therapeutics says MDS-UPDRS scores remain stable after 150 days of GT-2287 treatment - marketscreener.com
Gain Therapeutics presents phase 1b data on Parkinson’s drug By Investing.com - Investing.com Australia
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 - The Manila Times
Gain Therapeutics presents phase 1b data on Parkinson’s drug - Investing.com
Parkinson’s patients report better smell, sleep, balance on experimental GT-02287 - Stock Titan
Gain Therapeutics Inc. Q1 2026 Earnings: EPS Surprise Highlights Cost Discipline Amid Pre-Revenue StageShare Dilution Risk - newsline.com
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s - Yahoo Finance
Gain Therapeutics (GANX) Bounces Back: Testing Key Resistance at $1.87Overvalued Signals - Newser
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower Loss Surpasses Estimates, Stock Edges HigherSaaS Earnings Trends - Newser
Gain Therapeutics (GANX) Edges Higher as Biotech Sector Shows Mixed SignalsTrading Community Hub - Newser
Gain Therapeutics (GANX) Edges Higher as Shares Approach Key Resistance LevelPCR Extreme - newsline.com
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Gain Therapeutics Inc (GANX) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):